Bionomics is progressing BNC-210 to phase III trials in post-traumatic stress disorder (PTSD) following positive feedback from the U.S. FDA. Final data from the phase II Attune study were presented at the American College of Neuropsychopharmacology meeting in Arizona on Dec. 9, which showed that BNC-210 improved PTSD symptom severity at week 12 with efficacy observed as early as week four.